Appointments

Borden Ladner Gervais LLP (BLG) announces that Jay Lefton has joined the fi rm as a partner in its

Toronto offi ce. Lefton has more than 25 years of experience advising public and private companies on M&A, corporate and securities law, with a particular focus on technology and life sciences. In 2011, Jay was selected by his peers for inclusion in The Best Lawyers in Canada® and recognized in the International Who’s Who of Mergers & Acquisitions Lawyers and the Lexpert®/American Lawyer Guide to the Leading 500 Lawyers in Canada. Lefton currently sits on many boards including the Cell Therapy Advisory Board of Toronto’s Princess Margaret Hospital, the Ontario Genomics Institute, ThinkFirst Foundation of Canada, the Ontario Neurotrauma Foundation, Pathways to Education, Canadian Friends of Hebrew University and the Canadian Committee of Tel Aviv Foundation. He is also on the Board of Governors and the Research and Commercialization Committee of Toronto’s Mount Sinai Hospital. He has been a member of the Ontario Securities Commission’s Securities Advisory Committee assisting on various matters, including legislative and policy initiatives. He has also been an adjunct faculty member at Osgoode Hall Law School and has also instructed at the Rotman School of Management at the University of Toronto.

Novadaq Technologies Inc. has appointed Dr. David C. Martin as vice president, Business Development and Investor Relations. Prior to joining Novadaq, Dr. Martin worked as a healthcare analyst and investment banker with Dundee Securities and Yorkton Securities. Before that, he worked in sales and marketing for clinical diagnostics and biotechnology instrumentation companies, including Boehringer Mannheim and InterScience Inc. Dr. Martin has a Ph.D. (Biochemistry) from the University of Western Ontario, a M.Sc. (Biology) from the University of Toronto, and an MBA from the Richard Ivey School of Business.

Patheon announces the appointment of Michael E. Lytton as executive vice president, Corporate Development and Strategy and General Counsel. Lytton was most recently with Biogen Idec, Inc., where he held the position of executive vice president, Corporate and Business Development. Lytton’s 28-year career includes extensive experience in the pharmaceutical and biotech industry. Prior to joining Biogen Idec, Lytton was a general partner with Oxford Bioscience Partners, a venture capital fi rm investing in therapeutic, diagnostic, and life science tool companies. He has also practiced law for 17 years and specialized in representing biomedical companies; and is a past partner and member of the executive committee of the law fi rm Edwards Angell Palmer & Dodge as well as partner of the law fi rm Wilmer Hale. Currently he is chairman of the Board of Santhera Pharmaceuticals AG. He holds an undergraduate degree from Princeton University, a Master of Science degree in Epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K. where he was a Fulbright Scholar, and a Juris Doctor from Harvard Law School.

Cytochroma announces the appointments of Dr. Cynthia Lavoie and Osamu Otani to its Board of directors. Dr. Lavoie replaced Dr. Luc Marengère as VG Partners’ representative, and Mr. Otani replaced Dr. Seiichi Kiso as Mitsubishi Tanabe Pharma Corporation’s representative on the company’s Board. The number of Board members remains unchanged at six members. Dr. Lavoie is a Partner with VG Partners, part of VenGrowth Private Equity Partners Inc., and co-heads the management of the VenGrowth Advanced Life Sciences Fund Inc. She brings over 16 years of experience in research and industry and works closely with company management lending her technical and fi nancial expertise to operations as well as fi nancing, merger and exit transactions. Currently she sits on the boards of Axela, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics. Her prior experience includes positions as Investment Manager with the Ontario Genomics Institute where she initiated a seed fi nancing program and as Marketing Strategy consultant with a medical device and therapeutics company. Mr. Otani joined Tanabe Seiyaku Company Ltd. in 1983, and has served in managerial positions across International Development and project management, including general manager, Tanabe Seiyaku London Offi ce, and managing director, Mitsubishi Pharma Research & Development (Beijing). He has been president, Mitsubishi Tanabe Pharma Development America, Inc. since July 2010.

Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other infl ammatory diseases, announces that Martin Driscoll has been appointed as chief executive offi cer. Driscoll will lead the company as it progresses its lead compound further in clinical development. Driscoll has more than 30 years experience in the pharmaceutical industry, including senior roles in general management, commercial operations and business development for both privately held and publicly traded life science companies. He led the commercialization of several successful therapeutic products, the direct negotiation of multiple transactions, licensing and M&A and the successful submission of multiple major product regulatory fi lings. Prior to being elected CEO of Asmacure, Mr. Driscoll was CEO and a director of Javelin Pharmaceuticals, Inc., a publicly traded company focused on the development of acute care pain products, from March 2008 until July 2010, at which point he led the successful merger of the company with Hospira, Inc. Prior to his role with Javelin, Mr. Driscoll held senior managerial roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals. During his tenure at Schering-Plough, he also spent a signifi cant amount of time as general manager of Key Pharmaceuticals, the Schering unit responsible for all respiratory products marketed in the U.S. He holds a B.Sc. in Communications from the University of Texas at Austin. He has also been recently appointed as a member of the board of the Epilepsy Foundation of New Jersey and served on the Advisory Board for the American Lung Association.

real miracle